Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study

• Status: Unknown status
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

To study the impact of mirabegron, a B3-adrenoceptor agonist, in the treatment of ED in patients with LUTS secondary to BPH and concomitant ED.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Mirabegron; Tamsulosin

Criteria

Inclusion Criteria:

• Patients with concomitant ED and irritative LUTS secondary to BPH

• Married and sexually motivated.

Exclusion Criteria:

• Men with Peyronie's disease.

• Patients with contraindication to receive mirabegron (High PVR).

• Psychiatric disorders.

• Previous pelvic surgery or trauma

• Men with prostatic adenocarcinoma

• Patients refusing participating in the study